Key result
Rivaroxaban was associated with reduced hazards of recurrent VTE (19% reduction) and major bleeding (21% reduction) compared to warfarin in routine clinical practice.
Why the study?
Does rivaroxaban reduce recurrent VTE and major bleeding in adults with DVT or PE compared to warfarin in routine practice?
Cohort (n=45,853)
Does rivaroxaban reduce recurrent VTE and major bleeding in adults with DVT or PE compared to warfarin in routine practice?
Hazard Ratio: 0.81 (95% CI 0.73–0.9)
In routine clinical practice, rivaroxaban is associated with reduced risks of recurrent VTE and major bleeding compared to warfarin in patients with DVT or PE.
No takes yet. Share an insight, caveat, or question.
May support rivaroxaban preference in routine VTE care; hypothesis-generating and requires prospective confirmation.
Bunz et al. (2017) conducted a cohort in Venous thromboembolism (VTE) (n=45,853). Rivaroxaban vs. Warfarin was evaluated on Recurrent VTE (HR 0.81, 95% CI 0.73-0.90). Rivaroxaban was associated with reduced hazards of recurrent VTE (19% reduction) and major bleeding (21% reduction) compared to warfarin in routine clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: